DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
MaRS Excellence in Clinical Innovation and Technology Evaluation program
CADTH Symposium April 14 2015
Zayna Khayat I zkhayatmarsddcom I ZaynaKhayat
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
Poor pre-market quality clinical trial produces uncertainty
bull Accuracy versus clinical utility for diagnostic tests
bull No prospective economic analysis
bull Research failed to address health system perspectives
bull Me-too technologies
bull Lack of generalizability
bull Inadequate trial design eg randomizationconcealment ITT ndash leading to low quality evidence
Policy including non-affordability competing pressures
Evidence used to police adoption in isolation from originators of innovation
Is HTArsquos placement too late
Pre-Market Partnership formed April 2012 between government OHTAC the health system regulators academia clinicians and industry in selection by the health system and protocol design by all
Studies funded by industry
Streamlines path to adoption of disruptive technologies through a single harmonized process that meets regulatory and reimbursement requirements
Process includes evaluation systematic review economic analysis and ldquoconditions of adoptionrdquo analysis
Housed at MaRS a neutral innovation space (MaRS) which provides flow-through of funds secretariat coordinating and quality support
Executed by 4 academic Methodology Centres working with 24 Research Hospitals
EXCITE OverviewExcellence in Clinical Innovation and Technical Evaluation
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersJanuary2015
Concept
RegulationTIME
UPre-Market
Post-Market
Cost Effectiveness (CE)
Systematic review
Effectiveness
Obsolescence
Diffusion
Yes
Unconditional No
bull Efficacy Safety
bull Value (CE) Affordability
bull Ethical amp societal
bull Post-market conditions
E f f e c t i v e n e s s
Cost Effectiveness
Systematic review
bull Efficacy Safetybull Value (CE)
Affordabilitybull Ethical amp societalbull Post-market
conditions
Reimbursement
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
EXCITE Parallel value propositions
Industry Efficient HTA amp decision-
making Early engagement ndash prepare
infrastructure for adoption Alignment with regulator amp
broader innovation agenda Could decrease costs
Relevant issues addressed early
Mitigates re-submissions Alignment with health system
and broader innovation agenda
Access to new disruptive technologies ndash policy impacts publications
New methodological challenges Maintain independence
Single harmonized process for regulatory and reimbursement
More efficient economical and mitigates investment risk
Earlier feedback on technology Negotiate conditions of
adoption pre-launch
Academic Centres
PayerHTA Bodies
Regulator
Citizens Faster access to health technologies with a strong value proof
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
The EXCITE Collaboration Model
bull Dr Les Levin CSObull Dr Zayna Khayat Directorbull Adel Aziziyeh Project Managerbull Lily Lo Coordinator
bull Advice on science methodologybull Allocation of projectsbull Heads of 5 methodology centresbull Dr Les Levin CSO
bull Advise prioritization of technologiesbull Advice on clinical study designbull Support in conditions of adoptionbull Comprised of implementation sub-
committee of OHTAC
Management Board
bull Advice oversight directionbull Approve technologies protocol budgetbull Senior reps health economic development
HTA AHSCs industry
bull Review protocols for safetybull Chair Tony Easty
bull Excellence in complex clinical trial design and execution in collaboration with 24 Research Hospitalsbull Contracted in by EXCITE
bull Design study with industry bull Execute and publish the study
bull Early advice on design of the evidence package and study
Methodology Centres
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
bull Since April 2012 49 companies applied in 7 Calls for Innovation
bull Technologies selected
- 9 currently active (1 multinational 2 US 1 BC 5 Ont)
- 6 under review (to be approved at April 23 board)
bull Publicly discloseable projects are
- Home sleep apnea test- Renal denervation for hypertension (discontinued)- Rna disruption for early prediction of clinical
response to chemo in breast cancer- Electrical stimulation for voluntary upper limb
movements in stroke
Current state of the EXCITE program
November 2014
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 1 Conditions of Adoption
To read the full report visit wwwohicca
April2015
Projected Adoption Rates
Infrastructure Readiness
Reimbursement Considerations
Economic Projections
Knowledge Translation
Procurement
EXCITE + Office of Health Innovation to work collaboratively to prepare the system
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 2 Geographic expansion
April 2015
EXCITE International Planning Summit (March 27 2015)
bull UK ndash NICE NHS regulators AHSN
bull US ndash FDA BCBS Kaiser Mayohellipbull Canada ndash Industry Canada
Health Canada Federal Innov Panel
bull Ontario ndash MoHLTC CAHObull Industry ndash small and
multinational (Canada US UK NZ)
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters April2015
Zayna KhayatDirectorzkhayatmarsddcom
Lily LoAssociatellomarsddcom
Adel AziziyehProject Manageraaziziyehmarsddcom
Les LevinChief Scientific Officerllevinmarsddcom
For more information visit wwwexcitemarsddcomTwitter MaRSEXCITE
Or contact us at
- Slide 1
- Slide 2
- Slide 3
- Concept
- Slide 5
- Slide 6
- Current state of the EXCITE program
- Whatrsquos next 1 Conditions of Adoption
- Whatrsquos next 2 Geographic expansion
- Slide 10
-
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
Poor pre-market quality clinical trial produces uncertainty
bull Accuracy versus clinical utility for diagnostic tests
bull No prospective economic analysis
bull Research failed to address health system perspectives
bull Me-too technologies
bull Lack of generalizability
bull Inadequate trial design eg randomizationconcealment ITT ndash leading to low quality evidence
Policy including non-affordability competing pressures
Evidence used to police adoption in isolation from originators of innovation
Is HTArsquos placement too late
Pre-Market Partnership formed April 2012 between government OHTAC the health system regulators academia clinicians and industry in selection by the health system and protocol design by all
Studies funded by industry
Streamlines path to adoption of disruptive technologies through a single harmonized process that meets regulatory and reimbursement requirements
Process includes evaluation systematic review economic analysis and ldquoconditions of adoptionrdquo analysis
Housed at MaRS a neutral innovation space (MaRS) which provides flow-through of funds secretariat coordinating and quality support
Executed by 4 academic Methodology Centres working with 24 Research Hospitals
EXCITE OverviewExcellence in Clinical Innovation and Technical Evaluation
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersJanuary2015
Concept
RegulationTIME
UPre-Market
Post-Market
Cost Effectiveness (CE)
Systematic review
Effectiveness
Obsolescence
Diffusion
Yes
Unconditional No
bull Efficacy Safety
bull Value (CE) Affordability
bull Ethical amp societal
bull Post-market conditions
E f f e c t i v e n e s s
Cost Effectiveness
Systematic review
bull Efficacy Safetybull Value (CE)
Affordabilitybull Ethical amp societalbull Post-market
conditions
Reimbursement
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
EXCITE Parallel value propositions
Industry Efficient HTA amp decision-
making Early engagement ndash prepare
infrastructure for adoption Alignment with regulator amp
broader innovation agenda Could decrease costs
Relevant issues addressed early
Mitigates re-submissions Alignment with health system
and broader innovation agenda
Access to new disruptive technologies ndash policy impacts publications
New methodological challenges Maintain independence
Single harmonized process for regulatory and reimbursement
More efficient economical and mitigates investment risk
Earlier feedback on technology Negotiate conditions of
adoption pre-launch
Academic Centres
PayerHTA Bodies
Regulator
Citizens Faster access to health technologies with a strong value proof
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
The EXCITE Collaboration Model
bull Dr Les Levin CSObull Dr Zayna Khayat Directorbull Adel Aziziyeh Project Managerbull Lily Lo Coordinator
bull Advice on science methodologybull Allocation of projectsbull Heads of 5 methodology centresbull Dr Les Levin CSO
bull Advise prioritization of technologiesbull Advice on clinical study designbull Support in conditions of adoptionbull Comprised of implementation sub-
committee of OHTAC
Management Board
bull Advice oversight directionbull Approve technologies protocol budgetbull Senior reps health economic development
HTA AHSCs industry
bull Review protocols for safetybull Chair Tony Easty
bull Excellence in complex clinical trial design and execution in collaboration with 24 Research Hospitalsbull Contracted in by EXCITE
bull Design study with industry bull Execute and publish the study
bull Early advice on design of the evidence package and study
Methodology Centres
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
bull Since April 2012 49 companies applied in 7 Calls for Innovation
bull Technologies selected
- 9 currently active (1 multinational 2 US 1 BC 5 Ont)
- 6 under review (to be approved at April 23 board)
bull Publicly discloseable projects are
- Home sleep apnea test- Renal denervation for hypertension (discontinued)- Rna disruption for early prediction of clinical
response to chemo in breast cancer- Electrical stimulation for voluntary upper limb
movements in stroke
Current state of the EXCITE program
November 2014
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 1 Conditions of Adoption
To read the full report visit wwwohicca
April2015
Projected Adoption Rates
Infrastructure Readiness
Reimbursement Considerations
Economic Projections
Knowledge Translation
Procurement
EXCITE + Office of Health Innovation to work collaboratively to prepare the system
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 2 Geographic expansion
April 2015
EXCITE International Planning Summit (March 27 2015)
bull UK ndash NICE NHS regulators AHSN
bull US ndash FDA BCBS Kaiser Mayohellipbull Canada ndash Industry Canada
Health Canada Federal Innov Panel
bull Ontario ndash MoHLTC CAHObull Industry ndash small and
multinational (Canada US UK NZ)
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters April2015
Zayna KhayatDirectorzkhayatmarsddcom
Lily LoAssociatellomarsddcom
Adel AziziyehProject Manageraaziziyehmarsddcom
Les LevinChief Scientific Officerllevinmarsddcom
For more information visit wwwexcitemarsddcomTwitter MaRSEXCITE
Or contact us at
- Slide 1
- Slide 2
- Slide 3
- Concept
- Slide 5
- Slide 6
- Current state of the EXCITE program
- Whatrsquos next 1 Conditions of Adoption
- Whatrsquos next 2 Geographic expansion
- Slide 10
-
Pre-Market Partnership formed April 2012 between government OHTAC the health system regulators academia clinicians and industry in selection by the health system and protocol design by all
Studies funded by industry
Streamlines path to adoption of disruptive technologies through a single harmonized process that meets regulatory and reimbursement requirements
Process includes evaluation systematic review economic analysis and ldquoconditions of adoptionrdquo analysis
Housed at MaRS a neutral innovation space (MaRS) which provides flow-through of funds secretariat coordinating and quality support
Executed by 4 academic Methodology Centres working with 24 Research Hospitals
EXCITE OverviewExcellence in Clinical Innovation and Technical Evaluation
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersJanuary2015
Concept
RegulationTIME
UPre-Market
Post-Market
Cost Effectiveness (CE)
Systematic review
Effectiveness
Obsolescence
Diffusion
Yes
Unconditional No
bull Efficacy Safety
bull Value (CE) Affordability
bull Ethical amp societal
bull Post-market conditions
E f f e c t i v e n e s s
Cost Effectiveness
Systematic review
bull Efficacy Safetybull Value (CE)
Affordabilitybull Ethical amp societalbull Post-market
conditions
Reimbursement
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
EXCITE Parallel value propositions
Industry Efficient HTA amp decision-
making Early engagement ndash prepare
infrastructure for adoption Alignment with regulator amp
broader innovation agenda Could decrease costs
Relevant issues addressed early
Mitigates re-submissions Alignment with health system
and broader innovation agenda
Access to new disruptive technologies ndash policy impacts publications
New methodological challenges Maintain independence
Single harmonized process for regulatory and reimbursement
More efficient economical and mitigates investment risk
Earlier feedback on technology Negotiate conditions of
adoption pre-launch
Academic Centres
PayerHTA Bodies
Regulator
Citizens Faster access to health technologies with a strong value proof
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
The EXCITE Collaboration Model
bull Dr Les Levin CSObull Dr Zayna Khayat Directorbull Adel Aziziyeh Project Managerbull Lily Lo Coordinator
bull Advice on science methodologybull Allocation of projectsbull Heads of 5 methodology centresbull Dr Les Levin CSO
bull Advise prioritization of technologiesbull Advice on clinical study designbull Support in conditions of adoptionbull Comprised of implementation sub-
committee of OHTAC
Management Board
bull Advice oversight directionbull Approve technologies protocol budgetbull Senior reps health economic development
HTA AHSCs industry
bull Review protocols for safetybull Chair Tony Easty
bull Excellence in complex clinical trial design and execution in collaboration with 24 Research Hospitalsbull Contracted in by EXCITE
bull Design study with industry bull Execute and publish the study
bull Early advice on design of the evidence package and study
Methodology Centres
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
bull Since April 2012 49 companies applied in 7 Calls for Innovation
bull Technologies selected
- 9 currently active (1 multinational 2 US 1 BC 5 Ont)
- 6 under review (to be approved at April 23 board)
bull Publicly discloseable projects are
- Home sleep apnea test- Renal denervation for hypertension (discontinued)- Rna disruption for early prediction of clinical
response to chemo in breast cancer- Electrical stimulation for voluntary upper limb
movements in stroke
Current state of the EXCITE program
November 2014
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 1 Conditions of Adoption
To read the full report visit wwwohicca
April2015
Projected Adoption Rates
Infrastructure Readiness
Reimbursement Considerations
Economic Projections
Knowledge Translation
Procurement
EXCITE + Office of Health Innovation to work collaboratively to prepare the system
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 2 Geographic expansion
April 2015
EXCITE International Planning Summit (March 27 2015)
bull UK ndash NICE NHS regulators AHSN
bull US ndash FDA BCBS Kaiser Mayohellipbull Canada ndash Industry Canada
Health Canada Federal Innov Panel
bull Ontario ndash MoHLTC CAHObull Industry ndash small and
multinational (Canada US UK NZ)
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters April2015
Zayna KhayatDirectorzkhayatmarsddcom
Lily LoAssociatellomarsddcom
Adel AziziyehProject Manageraaziziyehmarsddcom
Les LevinChief Scientific Officerllevinmarsddcom
For more information visit wwwexcitemarsddcomTwitter MaRSEXCITE
Or contact us at
- Slide 1
- Slide 2
- Slide 3
- Concept
- Slide 5
- Slide 6
- Current state of the EXCITE program
- Whatrsquos next 1 Conditions of Adoption
- Whatrsquos next 2 Geographic expansion
- Slide 10
-
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersJanuary2015
Concept
RegulationTIME
UPre-Market
Post-Market
Cost Effectiveness (CE)
Systematic review
Effectiveness
Obsolescence
Diffusion
Yes
Unconditional No
bull Efficacy Safety
bull Value (CE) Affordability
bull Ethical amp societal
bull Post-market conditions
E f f e c t i v e n e s s
Cost Effectiveness
Systematic review
bull Efficacy Safetybull Value (CE)
Affordabilitybull Ethical amp societalbull Post-market
conditions
Reimbursement
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
EXCITE Parallel value propositions
Industry Efficient HTA amp decision-
making Early engagement ndash prepare
infrastructure for adoption Alignment with regulator amp
broader innovation agenda Could decrease costs
Relevant issues addressed early
Mitigates re-submissions Alignment with health system
and broader innovation agenda
Access to new disruptive technologies ndash policy impacts publications
New methodological challenges Maintain independence
Single harmonized process for regulatory and reimbursement
More efficient economical and mitigates investment risk
Earlier feedback on technology Negotiate conditions of
adoption pre-launch
Academic Centres
PayerHTA Bodies
Regulator
Citizens Faster access to health technologies with a strong value proof
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
The EXCITE Collaboration Model
bull Dr Les Levin CSObull Dr Zayna Khayat Directorbull Adel Aziziyeh Project Managerbull Lily Lo Coordinator
bull Advice on science methodologybull Allocation of projectsbull Heads of 5 methodology centresbull Dr Les Levin CSO
bull Advise prioritization of technologiesbull Advice on clinical study designbull Support in conditions of adoptionbull Comprised of implementation sub-
committee of OHTAC
Management Board
bull Advice oversight directionbull Approve technologies protocol budgetbull Senior reps health economic development
HTA AHSCs industry
bull Review protocols for safetybull Chair Tony Easty
bull Excellence in complex clinical trial design and execution in collaboration with 24 Research Hospitalsbull Contracted in by EXCITE
bull Design study with industry bull Execute and publish the study
bull Early advice on design of the evidence package and study
Methodology Centres
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
bull Since April 2012 49 companies applied in 7 Calls for Innovation
bull Technologies selected
- 9 currently active (1 multinational 2 US 1 BC 5 Ont)
- 6 under review (to be approved at April 23 board)
bull Publicly discloseable projects are
- Home sleep apnea test- Renal denervation for hypertension (discontinued)- Rna disruption for early prediction of clinical
response to chemo in breast cancer- Electrical stimulation for voluntary upper limb
movements in stroke
Current state of the EXCITE program
November 2014
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 1 Conditions of Adoption
To read the full report visit wwwohicca
April2015
Projected Adoption Rates
Infrastructure Readiness
Reimbursement Considerations
Economic Projections
Knowledge Translation
Procurement
EXCITE + Office of Health Innovation to work collaboratively to prepare the system
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 2 Geographic expansion
April 2015
EXCITE International Planning Summit (March 27 2015)
bull UK ndash NICE NHS regulators AHSN
bull US ndash FDA BCBS Kaiser Mayohellipbull Canada ndash Industry Canada
Health Canada Federal Innov Panel
bull Ontario ndash MoHLTC CAHObull Industry ndash small and
multinational (Canada US UK NZ)
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters April2015
Zayna KhayatDirectorzkhayatmarsddcom
Lily LoAssociatellomarsddcom
Adel AziziyehProject Manageraaziziyehmarsddcom
Les LevinChief Scientific Officerllevinmarsddcom
For more information visit wwwexcitemarsddcomTwitter MaRSEXCITE
Or contact us at
- Slide 1
- Slide 2
- Slide 3
- Concept
- Slide 5
- Slide 6
- Current state of the EXCITE program
- Whatrsquos next 1 Conditions of Adoption
- Whatrsquos next 2 Geographic expansion
- Slide 10
-
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
EXCITE Parallel value propositions
Industry Efficient HTA amp decision-
making Early engagement ndash prepare
infrastructure for adoption Alignment with regulator amp
broader innovation agenda Could decrease costs
Relevant issues addressed early
Mitigates re-submissions Alignment with health system
and broader innovation agenda
Access to new disruptive technologies ndash policy impacts publications
New methodological challenges Maintain independence
Single harmonized process for regulatory and reimbursement
More efficient economical and mitigates investment risk
Earlier feedback on technology Negotiate conditions of
adoption pre-launch
Academic Centres
PayerHTA Bodies
Regulator
Citizens Faster access to health technologies with a strong value proof
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
The EXCITE Collaboration Model
bull Dr Les Levin CSObull Dr Zayna Khayat Directorbull Adel Aziziyeh Project Managerbull Lily Lo Coordinator
bull Advice on science methodologybull Allocation of projectsbull Heads of 5 methodology centresbull Dr Les Levin CSO
bull Advise prioritization of technologiesbull Advice on clinical study designbull Support in conditions of adoptionbull Comprised of implementation sub-
committee of OHTAC
Management Board
bull Advice oversight directionbull Approve technologies protocol budgetbull Senior reps health economic development
HTA AHSCs industry
bull Review protocols for safetybull Chair Tony Easty
bull Excellence in complex clinical trial design and execution in collaboration with 24 Research Hospitalsbull Contracted in by EXCITE
bull Design study with industry bull Execute and publish the study
bull Early advice on design of the evidence package and study
Methodology Centres
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
bull Since April 2012 49 companies applied in 7 Calls for Innovation
bull Technologies selected
- 9 currently active (1 multinational 2 US 1 BC 5 Ont)
- 6 under review (to be approved at April 23 board)
bull Publicly discloseable projects are
- Home sleep apnea test- Renal denervation for hypertension (discontinued)- Rna disruption for early prediction of clinical
response to chemo in breast cancer- Electrical stimulation for voluntary upper limb
movements in stroke
Current state of the EXCITE program
November 2014
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 1 Conditions of Adoption
To read the full report visit wwwohicca
April2015
Projected Adoption Rates
Infrastructure Readiness
Reimbursement Considerations
Economic Projections
Knowledge Translation
Procurement
EXCITE + Office of Health Innovation to work collaboratively to prepare the system
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 2 Geographic expansion
April 2015
EXCITE International Planning Summit (March 27 2015)
bull UK ndash NICE NHS regulators AHSN
bull US ndash FDA BCBS Kaiser Mayohellipbull Canada ndash Industry Canada
Health Canada Federal Innov Panel
bull Ontario ndash MoHLTC CAHObull Industry ndash small and
multinational (Canada US UK NZ)
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters April2015
Zayna KhayatDirectorzkhayatmarsddcom
Lily LoAssociatellomarsddcom
Adel AziziyehProject Manageraaziziyehmarsddcom
Les LevinChief Scientific Officerllevinmarsddcom
For more information visit wwwexcitemarsddcomTwitter MaRSEXCITE
Or contact us at
- Slide 1
- Slide 2
- Slide 3
- Concept
- Slide 5
- Slide 6
- Current state of the EXCITE program
- Whatrsquos next 1 Conditions of Adoption
- Whatrsquos next 2 Geographic expansion
- Slide 10
-
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future MattersApril2015
The EXCITE Collaboration Model
bull Dr Les Levin CSObull Dr Zayna Khayat Directorbull Adel Aziziyeh Project Managerbull Lily Lo Coordinator
bull Advice on science methodologybull Allocation of projectsbull Heads of 5 methodology centresbull Dr Les Levin CSO
bull Advise prioritization of technologiesbull Advice on clinical study designbull Support in conditions of adoptionbull Comprised of implementation sub-
committee of OHTAC
Management Board
bull Advice oversight directionbull Approve technologies protocol budgetbull Senior reps health economic development
HTA AHSCs industry
bull Review protocols for safetybull Chair Tony Easty
bull Excellence in complex clinical trial design and execution in collaboration with 24 Research Hospitalsbull Contracted in by EXCITE
bull Design study with industry bull Execute and publish the study
bull Early advice on design of the evidence package and study
Methodology Centres
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
bull Since April 2012 49 companies applied in 7 Calls for Innovation
bull Technologies selected
- 9 currently active (1 multinational 2 US 1 BC 5 Ont)
- 6 under review (to be approved at April 23 board)
bull Publicly discloseable projects are
- Home sleep apnea test- Renal denervation for hypertension (discontinued)- Rna disruption for early prediction of clinical
response to chemo in breast cancer- Electrical stimulation for voluntary upper limb
movements in stroke
Current state of the EXCITE program
November 2014
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 1 Conditions of Adoption
To read the full report visit wwwohicca
April2015
Projected Adoption Rates
Infrastructure Readiness
Reimbursement Considerations
Economic Projections
Knowledge Translation
Procurement
EXCITE + Office of Health Innovation to work collaboratively to prepare the system
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 2 Geographic expansion
April 2015
EXCITE International Planning Summit (March 27 2015)
bull UK ndash NICE NHS regulators AHSN
bull US ndash FDA BCBS Kaiser Mayohellipbull Canada ndash Industry Canada
Health Canada Federal Innov Panel
bull Ontario ndash MoHLTC CAHObull Industry ndash small and
multinational (Canada US UK NZ)
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters April2015
Zayna KhayatDirectorzkhayatmarsddcom
Lily LoAssociatellomarsddcom
Adel AziziyehProject Manageraaziziyehmarsddcom
Les LevinChief Scientific Officerllevinmarsddcom
For more information visit wwwexcitemarsddcomTwitter MaRSEXCITE
Or contact us at
- Slide 1
- Slide 2
- Slide 3
- Concept
- Slide 5
- Slide 6
- Current state of the EXCITE program
- Whatrsquos next 1 Conditions of Adoption
- Whatrsquos next 2 Geographic expansion
- Slide 10
-
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
bull Since April 2012 49 companies applied in 7 Calls for Innovation
bull Technologies selected
- 9 currently active (1 multinational 2 US 1 BC 5 Ont)
- 6 under review (to be approved at April 23 board)
bull Publicly discloseable projects are
- Home sleep apnea test- Renal denervation for hypertension (discontinued)- Rna disruption for early prediction of clinical
response to chemo in breast cancer- Electrical stimulation for voluntary upper limb
movements in stroke
Current state of the EXCITE program
November 2014
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 1 Conditions of Adoption
To read the full report visit wwwohicca
April2015
Projected Adoption Rates
Infrastructure Readiness
Reimbursement Considerations
Economic Projections
Knowledge Translation
Procurement
EXCITE + Office of Health Innovation to work collaboratively to prepare the system
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 2 Geographic expansion
April 2015
EXCITE International Planning Summit (March 27 2015)
bull UK ndash NICE NHS regulators AHSN
bull US ndash FDA BCBS Kaiser Mayohellipbull Canada ndash Industry Canada
Health Canada Federal Innov Panel
bull Ontario ndash MoHLTC CAHObull Industry ndash small and
multinational (Canada US UK NZ)
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters April2015
Zayna KhayatDirectorzkhayatmarsddcom
Lily LoAssociatellomarsddcom
Adel AziziyehProject Manageraaziziyehmarsddcom
Les LevinChief Scientific Officerllevinmarsddcom
For more information visit wwwexcitemarsddcomTwitter MaRSEXCITE
Or contact us at
- Slide 1
- Slide 2
- Slide 3
- Concept
- Slide 5
- Slide 6
- Current state of the EXCITE program
- Whatrsquos next 1 Conditions of Adoption
- Whatrsquos next 2 Geographic expansion
- Slide 10
-
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 1 Conditions of Adoption
To read the full report visit wwwohicca
April2015
Projected Adoption Rates
Infrastructure Readiness
Reimbursement Considerations
Economic Projections
Knowledge Translation
Procurement
EXCITE + Office of Health Innovation to work collaboratively to prepare the system
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 2 Geographic expansion
April 2015
EXCITE International Planning Summit (March 27 2015)
bull UK ndash NICE NHS regulators AHSN
bull US ndash FDA BCBS Kaiser Mayohellipbull Canada ndash Industry Canada
Health Canada Federal Innov Panel
bull Ontario ndash MoHLTC CAHObull Industry ndash small and
multinational (Canada US UK NZ)
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters April2015
Zayna KhayatDirectorzkhayatmarsddcom
Lily LoAssociatellomarsddcom
Adel AziziyehProject Manageraaziziyehmarsddcom
Les LevinChief Scientific Officerllevinmarsddcom
For more information visit wwwexcitemarsddcomTwitter MaRSEXCITE
Or contact us at
- Slide 1
- Slide 2
- Slide 3
- Concept
- Slide 5
- Slide 6
- Current state of the EXCITE program
- Whatrsquos next 1 Conditions of Adoption
- Whatrsquos next 2 Geographic expansion
- Slide 10
-
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters
Whatrsquos next 2 Geographic expansion
April 2015
EXCITE International Planning Summit (March 27 2015)
bull UK ndash NICE NHS regulators AHSN
bull US ndash FDA BCBS Kaiser Mayohellipbull Canada ndash Industry Canada
Health Canada Federal Innov Panel
bull Ontario ndash MoHLTC CAHObull Industry ndash small and
multinational (Canada US UK NZ)
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters April2015
Zayna KhayatDirectorzkhayatmarsddcom
Lily LoAssociatellomarsddcom
Adel AziziyehProject Manageraaziziyehmarsddcom
Les LevinChief Scientific Officerllevinmarsddcom
For more information visit wwwexcitemarsddcomTwitter MaRSEXCITE
Or contact us at
- Slide 1
- Slide 2
- Slide 3
- Concept
- Slide 5
- Slide 6
- Current state of the EXCITE program
- Whatrsquos next 1 Conditions of Adoption
- Whatrsquos next 2 Geographic expansion
- Slide 10
-
DE
VE
LO
PI
NG
T
AL
EN
T
bull
GR
OW
IN
G
VE
NT
UR
ES
bull
OP
EN
IN
G
MA
RK
ET
S
Our Future Matters April2015
Zayna KhayatDirectorzkhayatmarsddcom
Lily LoAssociatellomarsddcom
Adel AziziyehProject Manageraaziziyehmarsddcom
Les LevinChief Scientific Officerllevinmarsddcom
For more information visit wwwexcitemarsddcomTwitter MaRSEXCITE
Or contact us at
- Slide 1
- Slide 2
- Slide 3
- Concept
- Slide 5
- Slide 6
- Current state of the EXCITE program
- Whatrsquos next 1 Conditions of Adoption
- Whatrsquos next 2 Geographic expansion
- Slide 10
-